Research and development expense in fiscal Q3 2025 -- $4.5 million versus $4.9 million in fiscal Q3 2024. Net loss -- $5.9 ...

And except as required by law, STRATA Skin Sciences disclaims any obligation to publicly update or revise any information to ...

Revenue declined 9.4% year over year, impacted by reduced advertising and customer experience disruptions tied to the ...

2025 Revenue Guidance -- Management expects full-year revenue of $30 million to $40 million, with Q4 guidance of $5 million ...

In Jim Cramer's "Stop Trading" segment on CNBC's Squawk on the Street program, the famous stock picker mentioned Amgen ...

As it turns out, select Wall Street analysts believe that these two stocks could gain at least 20% over the next year.

Clinical Outcomes -- Twelve-month study data for the Catamaran implant showed VAS scores decreased from 78.8 to 23, and ODI ...

FDA Alignment -- BioAtla ( BCAB 4.08%) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints ...

Record Revenue -- $14.2 million, up 35% year-over-year and 15% sequentially from Q2 2025. Recurring Revenue -- $6.5 million ...

Net Loss — TMC the metals company ( TMC 8.33%) reported a net loss of $184.5 million (46¢ per share), a widening from $20.5 ...

Trailing Twelve-Month Core Product Sales -- $37 million, a company record, up from $33.8 million, with distributor and ...

Ballast Asset Management trimmed its Solaris Energy Infrastructure (SEI) position in Q3, locking in some gains after the ...